Varun Beverages Ltd, PC Jeweller Ltd, Jai Corp Ltd and Tejas Networks Ltd are among the other gainers in the BSE's 'A' group today, 06 November 2019.

Sun Pharma Advanced Research Company Ltd surged 8.49% to Rs 154.7 at 11:48 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 4.24 lakh shares were traded on the counter so far as against the average daily volumes of 1.34 lakh shares in the past one month.

Varun Beverages Ltd spiked 7.92% to Rs 757.35. The stock was the second biggest gainer in 'A' group. On the BSE, 46857 shares were traded on the counter so far as against the average daily volumes of 12543 shares in the past one month.

PC Jeweller Ltd soared 7.26% to Rs 34.7. The stock was the third biggest gainer in 'A' group. On the BSE, 15.08 lakh shares were traded on the counter so far as against the average daily volumes of 7.73 lakh shares in the past one month.

Jai Corp Ltd rose 6.17% to Rs 96.4. The stock was the fourth biggest gainer in 'A' group. On the BSE, 4.15 lakh shares were traded on the counter so far as against the average daily volumes of 2.19 lakh shares in the past one month.

Tejas Networks Ltd gained 6.15% to Rs 82. The stock was the fifth biggest gainer in 'A' group. On the BSE, 3950 shares were traded on the counter so far as against the average daily volumes of 72851 shares in the past one month.

Powered by Capital Market - Live News

The license allows CMS to develop and commercialize multiple products in Mainland China, Hong Kong, Macao and Taiwan.

The initial term of the agreement shall be 20 years from the date of first commercial sale of each product in the territory and may be further extended as per mutual agreement between the parties.

This collaboration is a significant milestone as this is the first licensing deal by SPARC for China. China is the third largest pharmaceutical market in the world and holds significant commercial opportunity for SPARC, said Anil Raghavan, CEO of SPARC.

As per the agreement, SPARC is eligible to receive upfront payment, milestone payments and royalty on net sales of the products in territories.

SPARC reported a net loss of Rs 63.16 crore in Q2 September 2019, higher than net loss of Rs 2.58 crore Q2 September 2018. Revenue from operations slumped 71.98% to Rs 17.19 crore in Q2 September 2019 over Q2 September 2018.

Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company.

Powered by Capital Market - Live News

Net Loss of Sun Pharma Advanced Research Company reported to Rs 63.16 crore in the quarter ended September 2019 as against net loss of Rs 2.58 crore during the previous quarter ended September 2018. Sales declined 71.98% to Rs 17.19 crore in the quarter ended September 2019 as against Rs 61.35 crore during the previous quarter ended September 2018.

Powered by Capital Market - Live News

Revenue from operations slumped 71.98% to Rs 17.19 crore in Q2 September 2019 over Q2 September 2018.

The stock fell as much as 5.48% to hit an intraday low of Rs 135.50. The stock was currently trading higher by 1.85% at Rs 146.

On the BSE, 3.96 lakh shares were traded in the counter so far compared with average daily volumes of 1.29 lakh shares in the past two weeks. The stock hit a high of Rs 151.9 so far during the day.

Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company.

Powered by Capital Market - Live News